NanoViricides, Inc.
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
153B
NanoViricides, Inc. (NYSE-Amer.: NNVC) is a clinical stage nano-pharmaceutical company on the verge of revolutionizing the treatment of viral diseases, just as penicillin revolutionized the treatment of bacterial diseases.
Our lead drug candidate, NV-387, is a host-mimetic, broad-spectrum, chemical nanomachine that is designed to engulf the virus particles and destroy them, defining a new paradigm that we call “Re-Infection Inhibition”, which goes beyond antibodies and small chemicals.
NV-387 has completed Phase I clinical trial with no reportable adverse events.
NV-387 has demonstrated strong activity in treatment of lethal Coronavirus, RSV, Influenza, and Orthopoxvirus (MPox/Smallpox) animal models with efficacy and safety superior to existing drugs.
NV-HHV-1, mimicking HVEM, is a pan-herpesvirus drug candidate. It has completed non-clinical studies for treatment of VZV shingles rash.
NV-HIV-1, a pan-HIV drug candidate has demonstrated strong activity in SCID-hu-Thy-Liv models.
Company HQ City:
Shelton
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2005
Lead Product in Development:
NV-387 broad-spectrum antiviral to treat RSV, Influenza, COVID, MPox/SMallpox and many other viral diseases
CEO
Anil R. Diwan
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
NYSE
Ticker
NNVC
When you expect your next catalyst update?
NV-387 Phase II Clinical Trial Recruitment and then Top Line Information
What is your next catalyst (value inflection) update?
2025 CY Q3
Website
www.nanoviricides.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}